The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma

As a result of the anti-tumour activity observed in vitro and in vivo with combined anti-CD20 and anti-CD74 antibodies, we initiated a phase I/II trial of veltuzumab and milatuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). Patients received an induction of veltuzuma...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Haematol
Hlavní autoři: Christian, Beth A., Poi, Ming, Jones, Jeffrey A., Porcu, Pierluigi, Maddocks, Kami, Flynn, Joseph M., Benson, Don M., Phelps, Mitch A., Wei, Lai, Byrd, John C., Wegener, William A., Goldenberg, David M., Baiocchi, Robert A., Blum, Kristie A.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2015
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7297055/
https://ncbi.nlm.nih.gov/pubmed/25847298
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13354
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky